ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

8:00AM-8:15AM: Abstract Number: 0849

Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis

Plenary II (0849–0854)

8:15AM-8:30AM: Abstract Number: 0850

Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis

Plenary II (0849–0854)

8:30AM-8:45AM: Abstract Number: 0851

Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis

Plenary II (0849–0854)

8:45AM-9:00AM: Abstract Number: 0852

LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT

Plenary II (0849–0854)

9:00AM-9:15AM: Abstract Number: 0853

Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status

Plenary II (0849–0854)

9:15AM-9:30AM: Abstract Number: 0854

The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study

Plenary II (0849–0854)

10:00AM-10:15AM: Abstract Number: 0855

Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial

Abstracts: Antiphospholipid Syndrome (0855–0860)

10:00AM-10:15AM: Abstract Number: 0861

Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II: Basic & Translational Research (0861–0866)

10:00AM-10:15AM: Abstract Number: 0885

MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

10:00AM-10:15AM: Abstract Number: 0891

MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)

10:00AM-10:15AM: Abstract Number: 0867

NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation

Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)

10:00AM-10:15AM: Abstract Number: 0873

Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)

10:00AM-10:15AM: Abstract Number: 0879

Trajectories and risk factors of interstitial lung disease in limited cutaneous systemic sclerosis from the EUSTAR cohort

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

10:15AM-10:30AM: Abstract Number: 0886

A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

10:15AM-10:30AM: Abstract Number: 0880

Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

1
2
3
…
58
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].